Rheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb
Trial Parameters
Brief Summary
Ipsilateral popliteal venous the most common access for pharmacomechanical thrombectomy (PMT) in the treatment of acute deep venous thrombosis (DVT), but the result was not satisfactory. The investigators adjust the access to improve the thrombus clearance rate and reduce the incidence of post-thrombotic syndrome (PTS).
Eligibility Criteria
Inclusion Criteria: * Age between 18-80 years old; * Acute DVT with clinical symptoms occurred less than 14 days since the onset of disease; * DVT with thrombosis involving the iliac vein, common femoral vein, distal popliteal vein, and/or calf vein; * Informed consent signed by patients. Exclusion Criteria: * Patients with the previous history of the same side of lower-limb DVT; * Patients with plasma Creatinine level greater than 180umol/L; * Patients who are contraindicated to thrombolysis; * Patients with inferior vena cava thrombosis; * Patients who are known to be allergic to heparin, low molecular weight heparin, or contrast agent; * Patients who have participated in a clinical trial in the past three months; * Women during pregnancy and lactation * Patients with other diseases that may cause difficulty in the study or significantly shorten the life expectancy of patients (\<2 years); * Patients with autoimmune thrombopathy or thrombocytopenia (platelets \< 80·10⁹/L); * Patients